EPITAC

Live / Applied — Second extension granted (statement of use) (as of 28 Feb 2026)

What this means for you

Not registered yet, but its 27 Feb 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
98424138
Mark type
Stylized text
Filed
27 Feb 2024
Published for opposition
07 Jan 2025
Attorney of record
Alyssa M. Worsham

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of oncogenic and autoimmune diseases signals using protein degradation in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, pulmonology, pneumology, oncology, metabolism, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation using protein degradation for use in treating oncology indications, namely, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastrointestinal stromal tumor (GIST), Gastric, Muscle invasive bladder cancer (MIBC), Colorectal Carcinoma (CRC), and autoimmune disease, namely, Pemphigus Vulgaris, Myasthenia Gravis, Rheumatoid arthritis, and Lupus; pharmaceutical preparations for the treatment of infectious diseases, immunodeficiency diseases, metabolic disease, Urticaria, Mastocytosis, Asthma, Alzheimer’s disease, Parkinson’s Disease, Multiple sclerosis, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastrointestinal stromal tumor (GIST), Gastric, Muscle invasive bladder cancer (MIBC), Colorectal Carcinoma (CRC), and autoimmune disease, namely, Pemphigus Vulgaris, Myasthenia Gravis, Rheumatoid arthritis, and Lupus; pharmaceutical preparations, namely, targeted therapies that degrade disease driving membrane and extracellular proteins to treat oncology and autoimmune disease, namely, metabolic disease, Urticaria, Mastocytosis, Asthma, Alzheimer’s disease, Parkinson’s Disease, Multiple sclerosis, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastrointestinal stromal tumor (GIST), Gastric, Muscle invasive bladder cancer (MIBC), Colorectal Carcinoma (CRC), and autoimmune disease, namely, Pemphigus Vulgaris, Myasthenia Gravis, Rheumatoid arthritis, and Lupus
  • Class 042 — Scientific and technological services: Medical and pharmaceutical research services in relation to protein degradation; pharmaceutical research and development in relation to protein degradation; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, research and design services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical and biopharmaceutical products; providing evaluation testing for pharmaceutical and biopharmaceutical products featuring protein degradation; pre-clinical and non-clinical evaluation testing of pharmaceutical and biopharmaceutical products; pharmaceutical and biopharmaceutical research and development featuring protein degradation for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, metabolism, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases; medical and pharmaceutical research in relation to targeted therapies that degrade disease driving membrane and extracellular proteins

Owner

Prosecution history

  • 28 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 28 Feb 2026 — SOU EXTENSION 2 GRANTED
  • 27 Feb 2026 — SOU EXTENSION 2 FILED
  • 27 Feb 2026 — SOU TEAS EXTENSION RECEIVED
  • 16 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 16 Jul 2025 — SOU EXTENSION 1 GRANTED
  • 15 Jul 2025 — SOU EXTENSION 1 FILED
  • 15 Jul 2025 — SOU TEAS EXTENSION RECEIVED
  • 13 Mar 2025 — ASSIGNED TO EXAMINER
  • 04 Mar 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 07 Jan 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 07 Jan 2025 — PUBLISHED FOR OPPOSITION
  • 01 Jan 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 10 Dec 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 10 Dec 2024 — EXAMINER'S AMENDMENT ENTERED

View this trademark record on Marksy